Pliant Therapeutics, Inc. (NASDAQ:PLRX) Position Increased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 2.4% in the third quarter, Holdings Channel.com reports. The firm owned 1,318,308 shares of the company’s stock after acquiring an additional 31,221 shares during the quarter. Geode Capital Management LLC’s holdings in Pliant Therapeutics were worth $14,781,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PLRX. Great Point Partners LLC lifted its position in shares of Pliant Therapeutics by 42.4% in the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock worth $28,346,000 after purchasing an additional 785,000 shares in the last quarter. Candriam S.C.A. lifted its position in shares of Pliant Therapeutics by 52.0% in the second quarter. Candriam S.C.A. now owns 833,216 shares of the company’s stock worth $8,957,000 after purchasing an additional 285,216 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Pliant Therapeutics by 233.8% in the second quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock worth $2,724,000 after purchasing an additional 177,469 shares in the last quarter. Checkpoint Capital L.P. lifted its position in shares of Pliant Therapeutics by 63.7% in the third quarter. Checkpoint Capital L.P. now owns 380,000 shares of the company’s stock worth $4,260,000 after purchasing an additional 147,800 shares in the last quarter. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of Pliant Therapeutics in the second quarter worth approximately $1,372,000. 97.30% of the stock is owned by hedge funds and other institutional investors.

Pliant Therapeutics Trading Down 5.7 %

NASDAQ:PLRX opened at $12.79 on Tuesday. The stock’s 50 day moving average price is $13.98 and its 200 day moving average price is $12.90. Pliant Therapeutics, Inc. has a 52 week low of $10.22 and a 52 week high of $19.62. The company has a market capitalization of $778.32 million, a P/E ratio of -3.83 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26.

Analyst Ratings Changes

A number of research firms have recently issued reports on PLRX. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Friday, November 8th. Leerink Partners assumed coverage on Pliant Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, Leerink Partnrs upgraded Pliant Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.